Enforce activities to prevent hoarding of Covid-19 drug Remdesivir: DCGI
Advertisement
New Delhi: The Director Controller General of India (DCGI) has released a notice ordering all States and Union Territories to perform special surveillance and inquiry to avoid hoarding, black marketing, and overcharging for Remdesivir, a potential therapeutic candidate for Covid-19.
Remdesivir, a promising therapeutic candidate for Covid-19 is an adenosine analogue nucleotide prodrug administered intravenously. It acts by interacting with the viral RNA-dependent RNA polymerase and prevents viral replication by terminating RNA transcription prematurely.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.